Src kinase inhibitor PP2 regulates the biological characteristics of A549 cells via the PI3K/Akt signaling pathway

Dai,Xi; Wang,Li‑Jiao; Wu,Juan; Shi,Ya‑Xu; Li,Guo‑Ping; Yang,Xiao‑Qiong

doi:10.3892/ol.2018.9282

Src kinase inhibitor PP2 regulates the biological characteristics of A549 cells via the PI3K/Akt signaling pathway

Authors:
- Xi Dai
- Li‑Jiao Wang
- Juan Wu
- Ya‑Xu Shi
- Guo‑Ping Li
- Xiao‑Qiong Yang
View Affiliations

Affiliations: State Key laboratory of Quality Research in Chinese Medicine/Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Taipa, Macau SAR 999056, P.R. China, Respiratory Medicine Department, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China, Respiratory Medicine Department, The Second Chinese Medicine Hospital of Sichuan Province, Chengdu, Sichuan 610031, P.R. China, Department of Respiratory Medicine, The Third People's Hospital of Chengdu/Affiliated Hospital of Southwest Jiaotong University, Chengdu, Sichuan 610000, P.R. China
Published online on: August 8, 2018 https://doi.org/10.3892/ol.2018.9282
Pages: 5059-5065
Copyright: © Dai et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is one of the most prevalent types of cancer worldwide, with a poor prognosis for patients and a concomitant financial burden on society. There are a number of different pathological subtypes, with non‑small cell lung cancer (NSCLC) being the primary subtype. Although anticancer therapy has led to a marked improvement in the survival rate of patients in recent years, the survival rate remains poor. Potential reasons for this include a lack of early diagnosis and drug resistance, which is considered to be associated with mutations in components of signaling pathways, tumor suppressors and epidermal growth factor receptor, and certain other complex mechanisms to a certain extent. It is therefore imperative to develop novel therapies. In the present study, the pyrazolopyrimidine compound PP2 was used to inhibit Src family protein tyrosine kinases in A549 cells. It was demonstrated that PP2 was able to suppress cell viability, migration and invasion, and promote apoptosis via regulating the phosphoinositide 3‑kinase/protein kinase B/B‑cell lymphoma 2/caspase‑3 signaling pathway. PP2 may therefore be useful in anti‑NSCLC therapy in the future.

View Figures

View References

1	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
2	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
3	Nur U, Quaresma M, De Stavola B, Peake M and Rachet B: Inequalities in non-small cell lung cancer treatment and mortality. J Epidemiol Community Health. 69:985–992. 2015. View Article : Google Scholar : PubMed/NCBI
4	Molina JR, Yang P, Cassivi SD, Schild SE and Adjei AA: Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594. 2008. View Article : Google Scholar : PubMed/NCBI
5	Martin GS: The hunting of the Src. Nat Rev Mol Cell Biol. 2:467–475. 2001. View Article : Google Scholar : PubMed/NCBI
6	Mello AA, Leal MF, Rey JA, Pinto GR, Lamarão LM, Montenegro RC, Alves AP, Assumpção PP, Borges Bdo N, Smith MC and Burbano RR: Deregulated expression of SRC, LYN and CKB Kinases by DNA methylation and its potential role in gastric cancer invasiveness and metastasis. PLos One. 10:e01404922015. View Article : Google Scholar : PubMed/NCBI
7	Chen J, Elfiky A, Han M, Chen C and Saif MW: The role of Src in colon cancer and its therapeutic implications. Clin Colorectal Cancer. 13:5–13. 2014. View Article : Google Scholar : PubMed/NCBI
8	Nam K, Oh S, Lee KM, Yoo SA and Shin I: CD44 regulates cell proliferation, migration, and invasion via modulation of c-Src transcription in human breast cancer cells. Cell Signal. 27:1882–1894. 2015. View Article : Google Scholar : PubMed/NCBI
9	Je DW, O YM, Ji YG, Cho Y and Lee DH: The inhibition of SRC family kinase suppresses pancreatic cancer cell proliferation, migration, and invasion. Pancreas. 43:768–776. 2014. View Article : Google Scholar : PubMed/NCBI
10	Singh S, Trevino J, Bora-Singhal N, Coppola D, Haura E, Altiok S and Chellappan SP: EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer. Mol Cancer. 11:732012. View Article : Google Scholar : PubMed/NCBI
11	Min HY, Yun HJ, Lee JS, Lee HJ, Cho J, Jang HJ, Park SH, Liu D, Oh SH, Lee JJ, et al: Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer. Mol Cancer. 14:1132015. View Article : Google Scholar : PubMed/NCBI
12	Sutton P, Borgia JA, Bonomi P and Plate JM: Lyn, a Src family kinase, regulates activation of epidermal growth factor receptors in lung adenocarcinoma cells. Mol Cancer. 12:762013. View Article : Google Scholar : PubMed/NCBI
13	Phuchareon J, McCormick F, Eisele DW and Tetsu O: EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function. Proc Natl Acad Sci USA. 112:E3855–E3863. 2015. View Article : Google Scholar : PubMed/NCBI
14	Shi Y: Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell. 9:459–470. 2002. View Article : Google Scholar : PubMed/NCBI
15	Joseph B, Ekedahl J, Lewensohn R, Marchetti P, Formstecher P and Zhivotovsky B: Defective caspase-3 relocalization in non-small cell lung carcinoma. Oncogene. 20:2877–2888. 2001. View Article : Google Scholar : PubMed/NCBI
16	Fu YN, Yeh CL, Cheng HH, Yang CH, Tsai SF, Huang SF and Chen YR: EGFR mutants found in non-small cell lung cancer show different levels of sensitivity to suppression of Src: Implications in targeting therapy. Oncogene. 27:957–965. 2008. View Article : Google Scholar : PubMed/NCBI
17	Zeng H, Zheng R, Guo Y, Zhang S, Zou X, Wang N, Zhang L, Tang J, Chen J, Wei K, et al: Cancer survival in China, 2003–2005: A population-based study. Int J Cancer. 136:1921–1930. 2015. View Article : Google Scholar : PubMed/NCBI
18	Frame MC: Src in cancer: Deregulation and consequences for cell behaviour. Biochim Biophys Acta. 1602:114–130. 2002.PubMed/NCBI
19	Nam JS, Ino Y, Sakamoto M and Hirohashi S: Src family kinase inhibitor PP2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis. Clin Cancer Res. 8:2430–2436. 2002.PubMed/NCBI
20	Biscardi JS, Maa MC, Tice DA, Cox ME, Leu TH and Parsons SJ: C-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J Biol Chem. 274:8335–8343. 1999. View Article : Google Scholar : PubMed/NCBI
21	Sarris EG, Saif MW and Syrigos KN: The biological role of PI3K pathway in lung cancer. Pharmaceuticals (Basel). 5:1236–1264. 2012. View Article : Google Scholar : PubMed/NCBI
22	Engelman JA, Luo J and Cantley LC: The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 7:606–619. 2006. View Article : Google Scholar : PubMed/NCBI
23	Tsurutani J, Fukuoka J, Tsurutani H, Shih JH, Hewitt SM, Travis WD, Jen J and Dennis PA: Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. J Clin Oncol. 24:306–314. 2006. View Article : Google Scholar : PubMed/NCBI
24	Bose P, Rahmani M and Grant S: Coordinate PI3K pathway and Bcl-2 family disruption in AML. Oncotarget. 3:1499–1500. 2012. View Article : Google Scholar : PubMed/NCBI
25	Elmore S: Apoptosis: A review of programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI
26	Ahel I, Ahel D, Matsusaka T, Clark AJ, Pines J, Boulton SJ and West SC: Poly(ADP-ribose)-binding zinc finger motifs in DNA repair/checkpoint proteins. Nature. 451:81–85. 2008. View Article : Google Scholar : PubMed/NCBI
27	Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A and Nagata S: A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature. 391:43–50. 1998. View Article : Google Scholar : PubMed/NCBI